SARS-CoV-2 Lung Disease in a Patient with Pulmonary Sarcoidosis—Case Report

Opoka, Lucyna; Wyrostkiewicz, Dorota; Winek, Jolanta; Błasińska, Katarzyna; Miłkowska-Dymanowska, Joanna; Szturmowicz, Monika

doi:10.5603/arm.a2020.0199

Cited by 4 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have summarized the findings of seven case series and reports totaling 46 patients in Table 1. For sarcoidosis patients that do not require maintenance therapy, the current guidelines for COVID-19 appear to be acceptable (8,9). However, for those taking disease modifying antisarcoid agents, there is a concern that their immunosuppressive regimen may have unwanted side effects of prolonging or worsening COVID-19 disease course.…”

Section: Resultsmentioning

confidence: 99%

Treatment of COVID-19 in Patients With Sarcoidosis

et al. 2021

View full text Add to dashboard Cite

Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe different treatment modalities ranging from glucocorticoids to biologic medications. This review article summarizes seven case series and reports totaling 46 patients. While one case report suggested that sarcoidosis medications such as glucocorticoids may lengthen the COVID-19 disease course, another study with a larger registry suggests they do not. More studies are needed to elucidate an improvement in outcomes. It is possible that addition of TNF-alpha inhibitors at COVID-19 diagnosis decreases hospitalization rate. Overall, it is difficult to make firm conclusions regarding treatment given the heterogeneity of treatment modalities in the current literature. Our summarized findings are outlined with the opinions of sarcoidosis, pulmonary, and infectious disease experts in a flow chart that provides clinicians with our proposed management algorithm for sarcoidosis patients who develop COVID-19. We emphasize a need for exchange of information regarding management of COVID-19 in the setting of sarcoidosis to further improve treatment in this vulnerable population of patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Treatment of COVID-19 in Patients With Sarcoidosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Тем не менее у тех пациентов c саркоидозом, у которых развился COVID-19, СГКС не отягощали состояния и приводили к улучшению состояния. Авторы отмечали, что необходима высокая осведомленность пульмонологов для своевременной госпитализации и лечения пациентов с саркоидозом, инфицированных SARS-CoV-2, особенно с нарушением функции легких и/или множественными сопутствующими заболеваниями [24]. Результаты нашего исследования и публикации других авторов предполагают, что у пациентов с саркоидозом прогноз COVID-19 в основном определяется наличием сопутствующих заболеваний, которые обычно более распространены в этой конкретной популяции.…”

Section: клинический случайunclassified

Characteristics of patients with sarcoidosis who referred to a pulmonologist during the COVID-19 pandemic

Vizel,

Shakirova

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. During the COVID-19 pandemic, the first experience was gained in managing patients with sarcoidosis in the face of a dangerous viral infection, a combination of two diseases and vaccination against COVID-19. Publications on this issue remain ambiguous, which made it relevant to assess the management of patients with sarcoidosis during a pandemic and the features of vaccination of these patients.Aim. To assess the condition of patients with sarcoidosis who turned to a pulmonologist during the pandemic, to compare the parameters of patients with sarcoidosis who had and did not have COVID-19, with mild and severe course, as well as to evaluate the effectiveness and safety of vaccination.Materials and methods. The study was a retrospective, observational, non-interventional study. We included 299 patients who visited a pulmonologist in 176 (58.9%) of whom developed COVID-19 and 123 (41.1%) did not have a viral disease. Information on survivors of COVID-19 was collected using the COVIZ application. Data summarization and statistical processing were carried out using the SPPS-18 program (IBM) p < 0.05 values were considered statistically significant.Research results. Comparison of data of patients with sarcoidosis who fell ill and did not become ill with COVID-19 during the pandemic period showed that those who fell ill with this viral infection were significantly younger, more often had extrapulmonary manifestations of sarcoidosis. Patients did not differ in the radiation stage of sarcoidosis, the frequency of Löfgren’s syndrome, and the frequency of familial cases of granulomatosis. The use of methotrexate was accompanied by a higher incidence of COVID-19, the probability of getting sick was more than 3 times higher (OR = 3.39; 95% CI 1.12–10.28). Among those who received GCS (n = 49), those who received a dose of 10 mg prednisolone equivalent and above (OR = 12.056; CI95% 2.12–68.5) were more likely to develop COVID-19. The risk of developing COVID-19 in those who were not vaccinated was significantly higher than in those who received the vaccine after a viral illness (OR = 2.50; CI95% 1.75–3.58). One case of death is presented.Conclusion. A retrospective analysis of cases of sarcoidosis during the COVID-19 pandemic indicated a favorable course of both diseases when combined. Negative prognostic factors were the use of immunosuppressive therapy for sarcoidosis and severe comorbidities of the cardiovascular system. Vaccination against COVID-19 was effective and safe in patients with pulmonary sarcoidosis.

show abstract

“…Since the beginning of the pandemic, there have been a number of case series and reports that have sought to describe the clinical courses and treatment of COVID-19 in sarcoidosis patients. The literature reveals seven case series and reports, which include a total of 46 sarcoidosis patients who contracted COVID-19 [34][35][36][37][38][39][40]. Management of COVID-19 in these cases varied and consisted of treatments that are currently not recommended for treatment of COVID-19, such as various antivirals and antima-larials.…”

Section: How Should We Treat Coronavirus Disease-19 In Patients With ...mentioning

confidence: 99%

COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes

Kahlmann¹,

Manansala²,

Moor³

et al. 2021

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of reviewPatients with sarcoidosis may be at higher risk of coronavirus disease-19 (COVID-19) as over 90% of the patients have pulmonary involvement and many are treated with immunosuppressive agents. This review will summarize the current literature regarding sarcoidosis and COVID-19, with a particular focus on susceptibility, clinical outcomes, management, and approach to vaccination. Recent findingsData about COVID-19 and sarcoidosis include a number of case series and reports, cohort studies, and registries. Literature is not conclusive whether patients with sarcoidosis have increased susceptibility to COVID-19. Patients with moderate to severe impaired pulmonary function may be at increased risk of adverse outcomes and mortality. Whether immunosuppressive medication increases risk of COVID-19 severity or affects vaccination response is not yet clear. Novel approaches, such as telemedicine and home monitoring programs, are promising to ensure continuity of care for patients with sarcoidosis during the COVID-19 pandemic.

show abstract

SARS-CoV-2 Lung Disease in a Patient with Pulmonary Sarcoidosis—Case Report

Cited by 4 publications

References 16 publications

Treatment of COVID-19 in Patients With Sarcoidosis

Treatment of COVID-19 in Patients With Sarcoidosis

Characteristics of patients with sarcoidosis who referred to a pulmonologist during the COVID-19 pandemic

COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes

Contact Info

Product

Resources

About